Table 2 Epigenetic drugs combination with cancer therapy
From: Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance
Regulator | Epigenetic targeting agents | Chemotherapy | Conditions | Trial lD | |
|---|---|---|---|---|---|
Histone acetylation | HDAC | Panobinostat | Tamoxifen | Breast cancer | NCT00993642 |
Temozolomide | Melanoma | NCT00925132 | |||
Melphalan | Myeloma | NCT00743288 | |||
Bortezomib | Lymphoma | NCT00901147 | |||
Carboplatin | Hodgkin lymphoma | NCT01169636 | |||
Epirubicin | Ovarian cancer | NCT00878904 | |||
AR-42 | Decitabine | Acute myeloid leukemia | NCT01798901 | ||
Pomalidomide | Relapsed multiple myeloma | NCT02569320 | |||
ITF2357 | Hodgkin’s lymphoma | NCT00496431 | |||
Valproic Acid | Fludarabine | Chronic lymphocytic leukemia | NCT00524667 | ||
Belinostat | Platinum | Tumors of the thymus | NCT00589290 | ||
Entinostat | Azacitidine | Colorectal cancer | NCT01105377 | ||
Capecitabine | High Risk Breast Cancer | NCT03473639 | |||
Vorinostat | Ixabepilone | Breast cancer | NCT01084057 | ||
Tamoxifen | Breast cancer | NCT01194427 | |||
5-fluorouracil, Leucovorin and Oxaliplatin | Colorectal cancer | NCT00336141 | |||
Romidepsin | Gemcitabine | Solid tumors | NCT00379639 | ||
Histone methylation | LSD1 | SP-2577 | Topotecan | Ewing sarcoma | NCT03600649 |
Seclidemstat | Azacitidine | Chronic myelomonocytic leukemia | NCT04734990 | ||
CC-90011 | Cisplatin and Etoposide | Small cell lung cancer | NCT03850067 | ||
Iadademstat | Azacitidine and Venetoclax | Acute myeloid leukemia | NCT06357182 | ||
DNA methylation | DNMT | Azacitidine | CAPOX | Colorectal cancer | NCT01193517 |
Cyclophosphamide | Peripheral T-cell lymphoma | NCT05678933 | |||
Abraxane | Breast cancer | NCT00748553 | |||
Decitabine | Cyclophosphamide | Acute myeloid leukemia | NCT06383572 | ||
Platinum | Ovarian cancer | NCT00477386 | |||
Fludarabine phosphate | Myeloid malignancies | NCT06383572 | |||
Carboplatin-Paclitaxel | Ovarian cancer | NCT02159820 | |||
Guadecitabine | Carboplatin | Small cell lung cancer, Ovarian cancer | NCT03913455 NCT01696032 | ||
Cladribine | Acute myeloid leukemia | NCT02096055 | |||
Irinotecan | Colorectal cancer | NCT01896856 | |||
Histone acetylation | HDAC | Vorinostat | Pembrolizumab Tamoxifen | Breast cancer | NCT04190056 |
Breast neoplasms | NCT02395627 | ||||
Trastuzumab | Breast cancer | NCT00258349 | |||
Carboplatin Paclitaxel Bevacizumab | Non-small cell lung cancer | NCT00702572 | |||
Pomalidomide | Relapse/refractory multiple myeloma | NCT01979276 | |||
Belinostat | Tremelimumab Durvalumab | Urothelial Carcinoma | NCT05154994 | ||
Panobinostat | Ipilimumab | Melanoma | NCT02032810 | ||
Paclitaxel, Carboplatin Bevacizumab | Solid Tumors | NCT00556088 | |||
Entinostat | Pembrolizumab | Solid Tumors | NCT02909452 | ||
Nivolumab | Cholangiocarcinoma and Pancreatic Adenocarcinoma | NCT03250273 | |||
Histone methylation | EZH2 | Tulmimetostat | Pembrolizumab | Non-small cell lung cancer | NCT05467748 |
XNW5004 | Pembrolizumab | Nasopharyngeal carcinoma | NCT06022757 | ||
CPI-1205 | Ipilimumab | Melanoma and Non-small cell lung cancer | NCT03525795 | ||
SHR2554 | SHR1701 | B-cell Lymphomas | NCT04407741 | ||
LSD1 | ORY-1001 | Atezolizumab or Durvalumab | Small cell lung cancer | NCT06287775 | |
IMG-7289 | Atezolizumab | Small cell lung cancer | NCT05191797 | ||
SP-2577 | Pembrolizumab | Small cell ovarian cancer | NCT04611139 | ||
CC-90011 | Nivolumab | Small cell lung cancer or Non-small cell lung cancer | NCT04350463 | ||
Bomedemstat | Atezolizumab | Small cell lung cancer | NCT05191797 | ||
DNA methylation | DNMT | Azacytidine | Pembrolizumab | Carcinoma of colon and rectum | NCT02260440 NCT02512172 |
Acute myeloid leukemia | NCT02845297 NCT04284787 NCT03769532 | ||||
Non-small cell lung cancer | NCT02546986 | ||||
Hodgkin lymphoma | NCT05355051 | ||||
Ovarian cancer | NCT02900560 | ||||
Pancreatic ductal adenocarcinoma | NCT03264404 | ||||
Melanoma | NCT02816021 | ||||
Fallopian tube cancer | NCT02901899 | ||||
Nivolumab | Acute myeloid leukemia | NCT02397720 NCT03825367 NCT04913922 | |||
Non-small cell lung cancer | NCT01928576 | ||||
Head and neck squamous-cell carcinoma | NCT05317000 | ||||
Hodgkin lymphoma | NCT05162976 | ||||
Osteosarcoma | NCT03628209 | ||||
Durvalumab | Acute myeloid leukemia | NCT02775903 | |||
Ovarian cancer, Breast cancer | NCT02811497 | ||||
Pancreatic cancer | NCT04257448 | ||||
Non-small cell lung cancer | NCT02250326 | ||||
Peripheral T-cell lymphoma | NCT03161223 | ||||
Camrelizumab | Acute myeloid leukemia | NCT05772273 | |||
Peripheral T-Cell Lymphoma | NCT05559008 | ||||
Avelumab | Acute myeloid leukemia | NCT03390296 | |||
Spartalizumab | Acute myeloid leukemia | NCT03066648 | |||
Ipilimumab | Acute myeloid leukemia | NCT02397720 | |||
PF-04518600 | Acute myeloid leukemia | NCT03390296 | |||
Decitabine | Pembrolizumab | Acute myeloid leukemia | NCT02996474 NCT03969446 | ||
Peripheral Triple-negative Breast Cance | NCT05673200 | ||||
HER2-negative Breast Cancer | NCT02957968 | ||||
Non-small cell lung cancer | NCT03233724 | ||||
CNS solid tumors and Lymphomas | NCT03445858 | ||||
T-cell lymphoma | NCT03240211 | ||||
Nivolumab | Mucosal melanoma | NCT05089370 | |||
Acute myeloid leukemia | NCT04277442 | ||||
Non-small cell lung cancer | NCT02664181 | ||||
Myelodysplastic syndromes, Acute myeloid leukemia | NCT02664181 | ||||
Durvalumab | Head and neck cancer | NCT03019003 | |||
Camrelizumab | Hodgkin lymphoma | NCT0451061, NCT0325096, NCT0451408, NCT04233294 | |||
Primary mediastinal large B-cell lymphoma | NCT03346642 | ||||
Acute myeloid leukemia | NCT04353479 | ||||
Spartalizumab | Acute myeloid leukemia | NCT03066648 | |||
Ipilimumab | Acute myeloid leukemia | NCT02890329 | |||
Guadecitabine | Pembrolizumab | Lung cancer | NCT03220477 | ||
Non-small cell lung cancer/Castration-resistant prostatic cancer | NCT02998567 | ||||
Fallopian tube cancer | NCT02901899 | ||||
Nivolumab | Melanoma, Non-small cell lung cancer | NCT04250246 | |||
Durvalumab | Kidney cancer | NCT03308396 | |||
Small cell lung cancer | NCT03085849 | ||||
Hepatocellular carcinoma, Gallbladder cancer, Pancreatic cancer, Intrahepatic cholangiocarcinoma | NCT03257761 | ||||
Atezolizumab | Chronic myelomonocytic leukemia and Acute myeloid leukemia | NCT02935361 | |||
Acute myeloid leukemia | NCT02892318 | ||||
Ovarian, Fallopian tube, or Primary peritoneal cancer | NCT03206047 | ||||
Urothelial carcinoma | NCT03179943 | ||||
Tremelimumab | Small cell lung cancer | NCT03085849 | |||
Ipilimumab | Melanoma, Non-small cell lung cancer | NCT04250246 | |||
Melanoma | NCT02608437 | ||||
TET1/2/3 | Auranofin | Sirolimus | Ovarian cancer | NCT03456700 | |
Solid tumors or Non-Small cell lung cancer | NCT02126527 | ||||
Non-Small cell lung cancer or Small cell lung cancer | NCT01737502 | ||||
Histone acetylation | HDAC | Entinostat | Exemestane | Breast Cancer | NCT02820961 |
Vorinostat | Olaparib | Breast cancer, Metastatic breast cancer | NCT03742245 | ||
Anastrozole Letrozole Exemestane | Breast cancer | NCT01720602 | |||
lapatinib | Breast cancer, Neoplasm, Metastasis | NCT01118975 | |||
Bortezomib | Advanced multiple myeloma | NCT00111813 | |||
Multiple myeloma | NCT00310024 | ||||
Metastatic or Unresectable solid tumors | NCT00227513 | ||||
Glioblastoma multiforme | NCT00641706 | ||||
Romidepsin | Flavopiridol | Solid tumors | NCT00094978 | ||
Decitabine | Pulmonary and Pleural malignancies | NCT00037817 | |||
Leukemia, Myeloproliferative disorders, or Myelodysplastic syndromes | NCT00114257 | ||||
Alisertib | Aggressive B-cell lymphoma and T-cell lymphoma | NCT01897012 | |||
Bortezomib | Relapse/refractory multiple myeloma | NCT00431990 | |||
Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Indolent B-cell lymphoma, Peripheral T-cell lymphomas, and Cutaneous T-cell lymphoma | NCT00963274 | ||||
Pralatrexate | Lymphoid malignancies | NCT01947140 | |||
CC-486 | Lymphoid malignancies | NCT01998035 | |||
Erlotinib | Solid tumors | NCT01302808 | |||
Carfilzomib | Cutaneous T-cell lymphoma | NCT01738594 | |||
Refractory B-cell lymphoma and T-cell lymphoma | NCT02341014 | ||||
Panobinostat | Bicalutamide | Prostate Cancer | NCT00878436 | ||
Pemetrexed | Non-Small Cell Lung Cancer | NCT00907179 | |||
Histone methylation | EZH2 | Tazemetostat | Enzalutamide | Prostate cancer | NCT04179864 |
PF-06821497 | Enzalutamide | Prostate cancer | NCT06629779 | ||
Tazemetostat | Dabrafenib | Melanoma | NCT04557956 | ||
LSD1 | IMG-7289 | Venetoclax | Acute Myeloid Leukemia | NCT05597306 | |
CC-90011 | Venetoclax and Azacitidine | Acute Myeloid Leukemia | NCT04748848 | ||
DNA methylation | DNMTi | Azacitidine | Ivosidenib and Venetoclax | Hematologic malignancies | NCT03471260 |
Chidamide | T-cell lymphoma | NCT04480125 | |||
Entinostat | Non-small cell lung cancer | NCT00387465 | |||
SAR443579 | Hematological malignancies. | NCT06508489 | |||
Epacadosta | Non-small cell lung cancer and colorectal cancer | NCT02959437 | |||
Venetoclax | Acute myeloid leukemia | NCT05471700 | |||
Decitabine | Avapritinib | Hematologic neoplasm | NCT06327685 | ||
Panitumumab | Colorectal Cancer | NCT00879385 | |||
Tagraxofusp | Chronic myelomonocytic leukemia | NCT05038592 | |||
Enzalutamide | Prostate cancer | NCT05037500 | |||
Venetoclax | Acute myeloid leukemia | NCT05455294 | |||
MBG453 | Melanoma/Non-small cell lung cancer | NCT02608268 | |||
Selinexor | Ovarian cancer | NCT05983276 | |||
Ruxolitinib | Acute myeloid leukemia | NCT02076191 | |||
Guadecitabine | Pembrolizumab | Lung cancer | NCT03220477 | ||
Non-small cell lung cancer Prostatic cancer | NCT02998567 | ||||
Ovarian, Primary peritoneal or Fallopian tube cancer | NCT02901899 | ||||
Nivolumab | Melanoma, Non-small cell lung cancer | NCT04250246 | |||
Durvalumab | Advanced kidney cancer | NCT03308396 | |||
Small cell lung cancer | NCT03085849 | ||||
Hepatocellular carcinoma, Gallbladder cancer, Pancreatic cancer, Intrahepatic cholangiocarcinoma | NCT03257761 | ||||
Atezolizumab | Chronic myelomonocytic leukemia, Myelodysplastic syndromes and Acute myeloid leukemia | NCT02935361 | |||
Acute myeloid leukemia | NCT02892318 | ||||
Ovarian, Fallopian tube, or Primary peritoneal cancer | NCT03206047 | ||||
Urothelial carcinoma | NCT03179943 | ||||
Tremelimumab | Small cell lung cancer | NCT03085849 | |||
Ipilimumab | Melanoma | NCT02608437 | |||
Melanoma/Non-small cell lung cancer | NCT04250246 | ||||
Histone acetylation | HDAC | Vorinostat | Standard fractionation of 3.0 Gy per day, a total dose of 30 Gy | Non-Small cell lung cancer | NCT00821951 |
Dose of 50.4 Gy in 1.8 Gy fractions | Pancreatic cancer | NCT00831493 | |||
Fractionated stereotactic radiation therapy | Glioma | NCT01378481 | |||
1.8-Gy fractions to a total dose of 50.4 Gy | Pancreatic cancer | NCT02349867 | |||
Panobinostat | 10 fractions of stereotactic radiation therapy, over 2 weeks | Brain tumors | NCT01324635 | ||
Vorinostat | A dose of 70 Gy | Non-Small cell lung cancer | NCT01059552 | ||
Valproate | 2 Gy fraction from Monday | Cervical cancer | NCT00404326 | ||
Valproic Acid | 2 Gy fractions to 60 Gy | Brain tumors | NCT00302159 | ||
Histone methylation | EZH2 | Temozolomide | 2 Gy fractions to 60 Gy | Glioblastoma | NCT04396860 NCT03514069 NCT05739942 |
DNA methylation | DNMT | Decitabine | 2 Gy fraction 5 times per week | Lymphomas | NCT03445858 |
